[The hemodynamic effects of nifedipine in congestive cardiomyopathy (author's transl)].
The Authors present the haemodynamic effects of nifedipina (Adalat-Bayer) in nine patients with congestive cardiomyopathy. Heart rate (HR), systemic vascular resistances (SVR) and mean aortic blood pressure (MABP) were significantly modified in all nine patients following the administration of the drug. Six of them showed an increase of cardiac index (CI) and a decrease of myocardial oxygen consumption (MVO2); three of them presented a decrease of CI and an increase of MVO2. This discrepancy can be due to the different percentage of increase and to the maximal of valves of HR in the two groups. Nifedipina can be useful in the treatment of congestive cardiomyopathy with elevated STR (afterload) and peripheral hypoperfusion (more than pulmonary congestion).
D000293:Adolescent; D000328:Adult; D009202:Cardiomyopathies / Q000188:drug therapy*; D005260:Female; D006333:Heart Failure / Q000188:drug therapy; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009206:Myocardium / Q000378:metabolism; D009543:Nifedipine / Q000494:pharmacology / Q000627:therapeutic use*; D010101:Oxygen Consumption / Q000187:drug effects; D011725:Pyridines / Q000627:therapeutic use*; D014655:Vascular Resistance / Q000187:drug effects
D011725:Pyridines; D009543:Nifedipine
Effetti emodinamici della nifedipina nella cardiomiopatia congestizia.